2022年(nian)的政(zheng)府工作報告提(ti)出,支持(chi)(chi)中(zhong)醫藥(yao)振興發(fa)展(zhan),推進中(zhong)醫藥(yao)綜(zong)合(he)改革(ge)。在(zai)國(guo)家(jia)頂(ding)層(ceng)政(zheng)策支持(chi)(chi)、國(guo)際化等大背景(jing)下,中(zhong)醫藥(yao)行業有(you)著(zhu)巨大的成長空間(jian),各細(xi)分領域將迎來黃(huang)金(jin)發(fa)展(zhan)期。米內網數據顯示,預計2021年(nian)中(zhong)國(guo)城(cheng)市實體藥(yao)店(dian)婦科中(zhong)成藥(yao)市場規模超過50億元(yuan)。
從(cong)TOP20廠家(jia)(jia)格局來看,株洲(zhou)千(qian)金藥(yao)(yao)業、山西(xi)廣譽遠國藥(yao)(yao)、九(jiu)芝(zhi)堂、仲景宛(wan)西(xi)制藥(yao)(yao)、四(si)川恩威(wei)制藥(yao)(yao)位(wei)居(ju)前五(wu)。產(chan)品(pin)(pin)TOP20中(zhong)(zhong)(zhong)10個(ge)是獨家(jia)(jia),5個(ge)漲(zhang)超(chao)10%。在(zai)中(zhong)(zhong)(zhong)國城市實體藥(yao)(yao)店婦科中(zhong)(zhong)(zhong)成藥(yao)(yao)產(chan)品(pin)(pin)TOP20中(zhong)(zhong)(zhong),九(jiu)芝(zhi)堂驢(lv)膠補血(xue)顆(ke)粒占(zhan)市場份額3.45%,位(wei)居(ju)第四(si);在(zai)中(zhong)(zhong)(zhong)國城市實體藥(yao)(yao)店婦科中(zhong)(zhong)(zhong)成藥(yao)(yao)品(pin)(pin)牌TOP20中(zhong)(zhong)(zhong),九(jiu)芝(zhi)堂驢(lv)膠補血(xue)顆(ke)粒占(zhan)市場份額3.39%,位(wei)居(ju)第五(wu)。